Biogen projects 2026 revenue drop despite Q4 beat
Source: SeekingAlpha
2026-02-06 07:02:19 ET
More on Biogen
- Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma
- 44th Annual J.P. Morgan Healthcare Conference
- Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Biogen beats top-line and bottom-line estimates; initiates FY26 outlook
- Biogen Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Biogen projects 2026 revenue drop despite Q4 beat
Eisai Co
NASDAQ: ESAIY
ESAIY Trading
1.06% G/L:
$7.61 Last:
25,646 Volume:
$7.58 Open:
ESAIY Latest News
March 01, 2026 07:49:00 pm
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
February 16, 2026 02:03:00 am
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 09, 2026 11:34:00 pm
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 05, 2026 09:31:00 pm
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
